Manish Agarwal
Diabetologist, Medilink Hospital, India
Title: Effects of Saroglitazar in Diabetic Patients with High Triglyceride (TG> 150 mg/dl) – 24 weeks Observational Study
Biography:
Abstract:
Background: Diabetic Dyslipidemia (DD) is highly atherogenic condition, which is associated with high triglycerides (TG), high small dense low density lipoprotein cholesterol (sdLDL-C) and low high density lipoprotein cholesterol (HDL-C). In India, low HDL-C and high TG are commonly observed dyslipidemia pattern1. Saroglitazar, a dual PPAR α/γ (Peroxisome proliferator activated receptor) agonist, is approved in India for the treatment of diabetic dyslipidemia (DD) not controlled with statins.
Aims: This observational study was done to evaluate effect of Saroglitazar in type 2 diabetes patients with elevated TG (>150mg/dl) and safety profile at 12 and 24 weeks.
Method: Total 100 T2D patients were enrolled with TG>150 mg/dl and were given saroglitazar 4mg once daily for 24 weeks. The effects of saroglitazar on lipid and glycemic parameters, and safety by recording adverse events were evaluated at 12 weeks and 24 weeks by using paired t-test.
Results: At 12 weeks the primary end point showed a significant reduction in TG (from 155.42 ± 18.9 mg/dl to 128.33 ± 16.3 mg/dl; p<0.001) and non-HDL-C (from 173.02 ± 20.76 to 144.62 ± 16.0; p<0.001). These effect were continued upto 6 months, where significant reduction was observed in TG and Non-HDL from baseline by 29.8% (p<0.001), 26.6% (p<0.001), respectively. Of the secondary end points the values of TC, HDL-C, LDL-C and HbA1c were also significantly improved at 12 and 24 weeks (Table 1). No major adverse event reported during the study period.
Discussion: High TG should be reduced, if not controlled by statin therapy in diabetes patients. In this study, saroglitazar is reducing TG with other lipid parameters, without any major adverse events.
Manish Agarwal
Diabetologist, Medilink Hospital, India
Title: Effects of Saroglitazar in Diabetic Patients with High Triglyceride (TG> 150 mg/dl) – 24 weeks Observational Study
Biography:
Abstract:
Background: Diabetic Dyslipidemia (DD) is highly atherogenic condition, which is associated with high triglycerides (TG), high small dense low density lipoprotein cholesterol (sdLDL-C) and low high density lipoprotein cholesterol (HDL-C). In India, low HDL-C and high TG are commonly observed dyslipidemia pattern1. Saroglitazar, a dual PPAR α/γ (Peroxisome proliferator activated receptor) agonist, is approved in India for the treatment of diabetic dyslipidemia (DD) not controlled with statins.
Aims: This observational study was done to evaluate effect of Saroglitazar in type 2 diabetes patients with elevated TG (>150mg/dl) and safety profile at 12 and 24 weeks.
Method: Total 100 T2D patients were enrolled with TG>150 mg/dl and were given saroglitazar 4mg once daily for 24 weeks. The effects of saroglitazar on lipid and glycemic parameters, and safety by recording adverse events were evaluated at 12 weeks and 24 weeks by using paired t-test.
Results: At 12 weeks the primary end point showed a significant reduction in TG (from 155.42 ± 18.9 mg/dl to 128.33 ± 16.3 mg/dl; p<0.001) and non-HDL-C (from 173.02 ± 20.76 to 144.62 ± 16.0; p<0.001). These effect were continued upto 6 months, where significant reduction was observed in TG and Non-HDL from baseline by 29.8% (p<0.001), 26.6% (p<0.001), respectively. Of the secondary end points the values of TC, HDL-C, LDL-C and HbA1c were also significantly improved at 12 and 24 weeks (Table 1). No major adverse event reported during the study period.
Discussion: High TG should be reduced, if not controlled by statin therapy in diabetes patients. In this study, saroglitazar is reducing TG with other lipid parameters, without any major adverse events.